As of 2026-09-11 · the last 10 years
Research intensity has steadily declined over the last decade, falling from about 64% to about 47% of the element’s own all-time peak, which occurred in 1994.
Research intensity ran from about 64% of the element's own all-time peak in 2016 to about 47% in 2026 — a steady decline, and the all-time peak (1994) lies before this window. Over the same span its share of research attention across all elements fell. Among the 118 elements, palladium has a larger-than-average research literature.
The number of papers involving the element rose from about 11,507 in 2016 to about 19,366 in 2025 (1.68x). That is slower than the literature as a whole grew over the same years, so the element lost ground in the wider body of research even as its own count rose.
The core of palladium research remains anchored in Palladium Complexes in Asymmetric Cross-Coupling, a community focused on designing palladium complexes for Suzuki and Miyaura reactions with an emphasis on asymmetric catalysis. Palladium is central to this field, appearing in about 33% of its papers. However, this community’s share of palladium’s recent research has declined from 55.4% to 49.3%. A landmark 2016 review on palladium-catalyzed C–N cross-coupling reactions, cited over 2,900 times, remains a key reference, while recent work continues to explore atroposelective C–H functionalization.
A second significant area is Palladium Catalysis for Alcohol Oxidation and Hydrogen Synthesis, where palladium nanoparticles catalyze the oxidation of formic, methanol, and ethanol to generate hydrogen. Here, palladium is a minor presence in a much larger community, involved in about 4% of its papers. Its share of palladium research has remained steady at roughly 5%. Notable work includes a 2016 review on electrocatalysts for oxygen reduction, cited over 3,900 times, and recent studies on direct ethanol fuel cells.
Finally, Palladium Complexes as Platinum Analues in Anticancer Research involves synthesizing palladium complexes to evaluate their anticancer activity and DNA binding, often comparing them to platinum drugs. Palladium is a minor player here, present in about 3% of the community’s papers, with a steady share of about 5% of palladium research. This field is anchored by a 2018 review on photodynamic agents, cited over 540 times, and recent investigations into light-activated anticancer drugs.
Overall, the literature is consolidating away from its traditional strength in asymmetric cross-coupling, with the remainder of the research community—comprising various other applications—gaining share from 35.1% to 41.1% over the last two five-year periods.
For a deeper look at the current state of palladium research, see the Last 12 Months and Executive Brief reports.
What changed in the past year: new papers, shifting applications, emerging collaborators. See the momentum over a shorter window than the decade view.
Personal →See recent trends — Personal.
A by-topic status read of what changed and what's new — built for decision-makers, not search engines. Citation clusters, emerging applications, and the papers that matter most.
Professional →See the executive read — Professional.
These are the nine that matter most. There are more — browse all of them free.
Found one worth keeping? A free account remembers it for you, so you're not re-finding it every visit.
Showing Palladium's three strongest connections. Personal opens the slider and the whole 118-element graph.